To investigate the clinical and angiographic characteristics of systemic artery-to-pulmonary artery fistulas (SA-PAFs) in patients with noncancer-related hemoptysis undergoing bronchial artery embolization (BAE), and to assess their associations with procedural outcomes and recurrent hemoptysis. We retrospectively analyzed consecutive patients with noncancer-related hemoptysis treated with BAE between January 2020 and December 2024. Patients were categorized as having non-SA-PAF, mild SA-PAF, or massive SA-PAF on angiography. Clinical features, angiographic findings, embolization outcomes, and recurrence-free survival were compared. Cox regression analyses were used to identify factors associated with recurrence. Among 276 included patients, SA-PAFs were identified in 216 (78.3%), including 134 (48.6%) with mild SA-PAF and 82 (29.7%) with massive SA-PAF. Massive SA-PAF was associated with greater vascular complexity, including more culprit arteries and more frequent ectopic bronchial artery and non-bronchial systemic artery involvement. The overall clinical success rate was 98.2%, but complete cessation of hemoptysis was less frequent in the massive SA-PAF group (79.3%) than in the mild SA-PAF (91.0%) and non-SA-PAF (95.0%) groups. Among 271 patients with clinical success and follow-up, recurrence occurred in 54 (19.9%) and was most frequent in the massive SA-PAF group (32.9%). Recurrence-free survival was significantly worse in patients with massive SA-PAF. In the primary multivariable model, TB-related disease was independently associated with recurrence, whereas SA-PAF classification was not. In exploratory models, ectopic bronchial artery was independently associated with recurrence. SA-PAFs are common angiographic findings in noncancer-related hemoptysis treated with BAE. Massive SA-PAF is associated with greater vascular complexity and poorer unadjusted outcomes, whereas TB-related disease remained the most robust independent predictor of recurrence and ectopic bronchial artery may represent an additional exploratory angiographic marker.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: